GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$46.86 USD
-0.08 (-0.17%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $46.85 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GSK 46.86 -0.08(-0.17%)
Will GSK be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GSK
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Here's Why GSK (GSK) is a Strong Growth Stock
Other News for GSK
GSK forms Narrow Range Bar on October 31
New 52 Week Closing High appears for GSK after 2.2% move
GSK Advances Share Buyback Program with Recent Purchase
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
GSK Executives Sell Significant Shares on London Stock Exchange